Under40 community |

02 Ago Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Posted at 22:53h in Submission by Carmelo 0 Comments

0 Likes

Secondary myeloid neoplasms (sMN) are late events in non-transplanted acquired aplastic anemia (AA) or paroxysmal nocturnal hemoglobinuria (PNH) patients. This retrospective, multinational study (n=1008) reports how clinical, cytogenetic, and molecular characteristics influence the risk of sMN, suggesting rational diagnostic approaches. sMN presented high-risk morphological, cytogenetic, and...

28 Lug Clinical and Molecular Determinants of Clonal Evolution in 2 Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Posted at 17:02h in Submission by Carmelo 0 Comments

0 Likes

09 Set Response To BNT162b2 SARS-Cov-2 Vaccine In Recipients Of Allogeneic Hematopoietic Stem Cell Transplant

Posted at 10:20h in Submission by Francesco Saraceni 0 Comments

0 Likes

già sottomessa...

08 Set TP53 germline mutations in Childhood Hypodiploid ALL

Posted at 18:08h in Submission by Laura Rachele 0 Comments

0 Likes

Background: The hallmark of low-hpodiploid ALL are variants in TP53, the majority of which are germline. This suggests that hypodiploid ALL may be one manifestation of Li-Fraumeni syndrome. Objectives: This project aims to dissect TP53 variants in an Italian cohort of hypodiploid paediatric ALL patients and...

06 Set Clinical and immunological characterization of hMDS

Posted at 23:55h in Submission by giuliacalabretto 0 Comments

0 Likes

Hypocellular Myelodysplastic Syndromes (hMDS) are a rare subset of MDS, defined by a reduced age-adjusted bone marrow (BM) cellularity, irrespective of their WHO classification. The distinctive features of hMDS suggest an immune-mediated pathogenesis. A selective response to immunosuppressive therapy (IST), indeed, has been observed in...

06 Set PROGNOSTIC IMPACT OF MINIMAL REDISUAL DISEASE ASSESSMENT IN ELDERLY PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA. A COMPARISON BETWEEN CPX-351 AND INTENSIFIED FLUDARABINE-BASED REGIMENS

Posted at 23:25h in Submission by carola 0 Comments

0 Likes

Minimal residual disease (MRD) assessment retains high prognostic value in Acute Myeloid Leukemia patients (AML) undergoing intensive induction therapy. Secondary AML (s-AML) and therapy-related AML (t-AML) are usually under-represented in trial and are unlikely to respond to conventional induction and only few data are available...

06 Set Letermovir prophylaxis in HSCT patients

Posted at 23:10h in Submission by Giulia 0 Comments

0 Likes

Cytomegalovirus infection is one of the most common complications after allogeneic stem-cell transplantation (HSCT) still associated with significant morbidity and mortality. Although pre-emptive therapy (PET) is routinely used in the treatment of CMV after HSCT, its use is limited by unacceptable toxicities. Letermovir is the...

06 Set Non-leukemic cells define T-cell Large Granular Lymphocyte Leukemia subsets

Posted at 20:23h in Submission by Cristina 0 Comments

0 Likes

T-cell Large Granular Lymphocyte Leukemia (T-LGLL) is a chronic lymphoproliferative disorder characterized by the clonal expansion of T-LGL. Immunophenotype and mutational status discriminate symptomatic (i.e. CD8+ STAT3 mutated cases) from indolent patients [CD8+ STAT3 wild-type and CD4+ T-LGLL]. Several pro-inflammatory cytokines are known to play...

06 Set CD19/CD22 CAR T cells generated with Sleeping Beauty: full speed ahead towards B-ALL multi-targeting

Posted at 20:19h in Submission by Alex 0 Comments

0 Likes

Chimeric antigen receptor (CARs) have demonstrated remarkable success in the treatment of relapsed and refractory lymphoid malignancies. Despite a response rate of 60–90% at 1 month and a survival of 70% at 6 months, selective pressure and tumor plasticity led to the appearance of CD19-negative relapses in...

06 Set Effect of oral iron treatments in Mask mice

Posted at 19:45h in Submission by michela.asperti 0 Comments

0 Likes

Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder due to genetic mutations on TMPRSS6 gene which encodes Matriptase2 (MT2). An altered MT2 cannot appropriately suppress hepatic BMP6/SMAD signaling in case of low iron, thus hepcidin excess blocks dietary iron absorption, leading to a...